Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III PRM-151 in idiopathic pulmonary fibrosis
NL-OMON52256Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing PRM-151 with Placebo (2 arms). Primary endpoint: Absolute change from baseline to Week 52 in forced vital capacity. Started Oct 2021; status: active, not recruiting.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON52256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52256.